Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma

Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma

Show other versions (1)

Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understoo...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Berair, R, Pavord, I
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2013

Eitemau Tebyg

Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
gan: Berair, R, et al.
Cyhoeddwyd: (2013)

Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
gan: Shrimanker, R, et al.
Cyhoeddwyd: (2017)

Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
gan: Xue, L, et al.
Cyhoeddwyd: (2015)

Interleukin-5 in the Pathophysiology of Severe Asthma
gan: Corrado Pelaia, et al.
Cyhoeddwyd: (2019-12-01)

Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma.
gan: Desai, D, et al.
Cyhoeddwyd: (2013)

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma
gan: Bart Hilvering, et al.
Cyhoeddwyd: (2015-08-01)

Anti-interleukin-5 therapy in severe asthma
gan: Gilles Garcia, et al.
Cyhoeddwyd: (2013-09-01)

Bronchial asthma and interleukin-5
gan: Das Undurti, et al.
Cyhoeddwyd: (2001-02-01)

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD
gan: Nora Drick, et al.
Cyhoeddwyd: (2022-10-01)

Emerging biologics in severe asthma
gan: Pavord, I, et al.
Cyhoeddwyd: (2016)

Mepolizumab, quality of life, and severe eosinophilic asthma.
gan: Pavord, I
Cyhoeddwyd: (2017)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
gan: Pelaia C, et al.
Cyhoeddwyd: (2017-10-01)

Possible Role for Interleukin-5 in Asthma
gan: Yacoob Y. Al-Rubaeyi, et al.
Cyhoeddwyd: (2007-01-01)

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma
gan: Trivedi, A, et al.
Cyhoeddwyd: (2016)

Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity
gan: Fatemeh Saheb Sharif-Askari, et al.
Cyhoeddwyd: (2021-07-01)

Controversies in allergy: should severe asthma with eosinophilic phenotype always be treated with anti-IL-5 therapies
gan: Pavord, I, et al.
Cyhoeddwyd: (2019)

Targeted deletion of Interleukin-3 results in asthma exacerbations
gan: Julia Kölle, et al.
Cyhoeddwyd: (2022-06-01)

Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial
gan: Lina Brinkmann, et al.
Cyhoeddwyd: (2024-11-01)

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma
gan: Nora Drick, et al.
Cyhoeddwyd: (2023-05-01)

Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register
gan: Marianne Baastrup Soendergaard, et al.
Cyhoeddwyd: (2022-10-01)

Bronchial thermoplasty for the treatment of asthma.
gan: Martin, N, et al.
Cyhoeddwyd: (2009)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
gan: Howell, I, et al.
Cyhoeddwyd: (2024)

Mepolizumab treatment in patients with severe eosinophilic asthma.
gan: Ortega, H, et al.
Cyhoeddwyd: (2014)

Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series
gan: Clairelyne Dupin, et al.
Cyhoeddwyd: (2024-02-01)

Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study
gan: Laura Mattei, et al.
Cyhoeddwyd: (2021-10-01)

Treatment of severe covid-19 with interleukin 6 receptor inhibition
gan: Stephen Burgess, et al.
Cyhoeddwyd: (2022-12-01)

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
gan: Florence Roufosse
Cyhoeddwyd: (2018-04-01)

Biomarkers for severe eosinophilic asthma.
gan: Yancey, S, et al.
Cyhoeddwyd: (2017)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
gan: Gunsoy, N, et al.
Cyhoeddwyd: (2017)

Is the neutrophil the key effector cell in severe asthma?
gan: Kamath, A, et al.
Cyhoeddwyd: (2005)

Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists
gan: Borish Larry, et al.
Cyhoeddwyd: (2001-02-01)

Role of interleukin-4 receptor α polymorphism in patients with asthma and its correlation with asthma severity
gan: Nidhi Girdhar, et al.
Cyhoeddwyd: (2025-01-01)

Will I get addicted to my asthma treatment?
gan: Pavord, I, et al.
Cyhoeddwyd: (1991)

Role of Interleukin 5 Inhibition in the Treatment of Eosinophilic Otitis Media
gan: Nathaniel K. Breslin, et al.
Cyhoeddwyd: (2021-02-01)

How I do it: workup of severe asthma
gan: Couillard, S, et al.
Cyhoeddwyd: (2021)

Interleukin-4 (C590T) Gene Polymorphism in Association with Asthma Severity
gan: Al-Ahmad M, et al.
Cyhoeddwyd: (2023-11-01)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
gan: Diego Bagnasco, et al.
Cyhoeddwyd: (2017-08-01)

Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma.
gan: Brightling, C, et al.
Cyhoeddwyd: (2003)

Noneosinophilic asthma: a distinct clinical and pathologic phenotype.
gan: Haldar, P, et al.
Cyhoeddwyd: (2007)

Evidence for interleukin-5 in nasal polyps in aspirin-induced asthma
gan: Norihisa Ogata, et al.
Cyhoeddwyd: (1997-01-01)